Logiq, Inc. Finalizes Acquisition of MedLab Essentials, LLC in $100MM Valuation Deal
Logiq, Inc. (OTC:LGIQ) has announced a definitive agreement to acquire MedLab Essentials, , a leader in cell and gene therapy innovation, in a deal valued at $100 million. The acquisition will be executed through a share exchange, with MedLab becoming a wholly owned subsidiary of Logiq. Key highlights include:
1. Logiq shareholders will retain 15% post-transaction
2. The combined entity aims to uplist to Nasdaq, CBOE, or NYSE
3. A substantial capital raise is planned by the end of 2024
4. This marks Logiq's first step in a series of biotech acquisitions targeting a cumulative value over $750 million
This strategic move signifies Logiq's diversification into the biotech sector, particularly focusing on cell and gene therapy assets.
Logiq, Inc. (OTC:LGIQ) ha annunciato un accordo definitivo per acquisire MedLab Essentials, un leader nell'innovazione della terapia cellulare e genica, in un'operazione del valore di 100 milioni di dollari. L'acquisizione sarà effettuata tramite uno scambio azionario, con MedLab che diventerà una controllata interamente posseduta da Logiq. I punti salienti includono:
1. Gli azionisti di Logiq manterranno il 15% post-operazione
2. L'entità combinata mira a quotarsi su Nasdaq, CBOE, o NYSE
3. È prevista una significativa raccolta di capitali entro la fine del 2024
4. Questo segna il primo passo di Logiq in una serie di acquisizioni nel settore biotech che punta a un valore cumulativo superiore a 750 milioni di dollari
Questa mossa strategica indica la diversificazione di Logiq nel settore biotech, concentrandosi in particolare sulle risorse relative alla terapia cellulare e genica.
Logiq, Inc. (OTC:LGIQ) ha anunciado un acuerdo definitivo para adquirir MedLab Essentials, un líder en innovación en terapia celular y genética, en una operación valorada en 100 millones de dólares. La adquisición se llevará a cabo mediante un intercambio de acciones, con MedLab convirtiéndose en una subsidiaria de propiedad total de Logiq. Los aspectos clave incluyen:
1. Los accionistas de Logiq retendrán el 15% después de la transacción
2. La entidad combinada tiene como objetivo cotizar en Nasdaq, CBOE o NYSE
3. Se planea una importante recaudación de capital para finales de 2024
4. Este es el primer paso de Logiq en una serie de adquisiciones biotecnológicas que apuntan a un valor acumulado de más de 750 millones de dólares
Este movimiento estratégico significa la diversificación de Logiq en el sector biotecnológico, enfocándose particularmente en activos de terapia celular y genética.
Logiq, Inc. (OTC:LGIQ)는 MedLab Essentials를 인수하기 위한 확정 계약을 발표했습니다. MedLab Essentials는 세포 및 유전자 치료 혁신 분야의 선두주자로, 이번 거래 가치는 1억 달러입니다. 인수는 주식 교환을 통해 이루어지며, MedLab은 Logiq의 완전 자회사로 편입됩니다. 주요 사항은 다음과 같습니다:
1. Logiq의 주주들은 거래 후 15%를 유지합니다.
2. 결합된 회사는 Nasdaq, CBOE 또는 NYSE에 상장할 계획입니다.
3. 2024년 말까지 상당한 자본 조달이 계획되어 있습니다.
4. 이는 Logiq이 7억 5천만 달러 이상의 누적 가치를 목표로 하는 생명과학 인수의 첫 번째 단계입니다.
이 전략적 움직임은 Logiq이 생명과학 분야로 다각화하고 있으며, 특히 세포 및 유전자 치료 자산에 집중하고 있음을 의미합니다.
Logiq, Inc. (OTC:LGIQ) a annoncé un accord définitif pour acquérir MedLab Essentials, un leader dans l'innovation en thérapie cellulaire et génique, dans une opération d'une valeur de 100 millions de dollars. L'acquisition se fera par échange d'actions, MedLab devenant une filiale entièrement détenue de Logiq. Les points clés incluent :
1. Les actionnaires de Logiq conserveront 15 % après la transaction
2. L'entité combinée vise à être cotée au Nasdaq, CBOE ou NYSE
3. Une levée de fonds substantielle est prévue d'ici la fin de 2024
4. Cela représente le premier pas de Logiq dans une série d'acquisitions biotechnologiques visant une valeur cumulée supérieure à 750 millions de dollars
Ce mouvement stratégique signifie la diversification de Logiq dans le secteur biotechnologique, en se concentrant particulièrement sur les actifs de thérapie cellulaire et génique.
Logiq, Inc. (OTC:LGIQ) hat eine endgültige Vereinbarung zur Übernahme von MedLab Essentials bekannt gegeben, einem führenden Unternehmen im Bereich Zell- und Gentherapie-Innovation, im Rahmen eines Deals im Wert von 100 Millionen Dollar. Die Übernahme erfolgt durch einen Aktientausch, wobei MedLab eine zu 100% im Besitz von Logiq befindliche Tochtergesellschaft wird. Zu den wichtigsten Punkten gehören:
1. Die Aktionäre von Logiq behalten 15% nach der Transaktion
2. Das kombinierte Unternehmen strebt eine Notierung an der Nasdaq, CBOE oder NYSE an
3. Eine erhebliche Kapitalerhöhung ist bis Ende 2024 geplant
4. Dies markiert den ersten Schritt von Logiq in einer Reihe von Übernahmen im Biotech-Sektor mit einem kumulierten Zielwert von über 750 Millionen Dollar
Dieser strategische Schritt bedeutet die Diversifizierung von Logiq in den Biotech-Sektor, mit besonderen Fokus auf Zell- und Gentherapie-Ressourcen.
- Acquisition valued at $100 million, indicating significant growth potential
- Planned uplisting to major exchanges (Nasdaq, CBOE, or NYSE) could increase visibility and liquidity
- Diversification into the high-growth biotech and cell and gene therapy sectors
- First in a series of planned acquisitions, targeting over $750 million in cumulative value
- Substantial capital raise planned by end of 2024, potentially strengthening financial position
- Significant dilution for current Logiq shareholders, retaining only 15% post-transaction
- Risks associated with integrating a new business in a different sector
- Potential challenges in meeting uplisting requirements and completing planned capital raise
- Execution risks in planned series of acquisitions totaling over $750 million
NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Logiq, Inc. (OTC Markets:LGIQ) ("Logiq" or "the Company"), today announced the definitive agreement to acquire MedLab Essentials, LLC ("MedLab"), a trailblazer in cell and gene therapy innovation. Logiq will acquire MedLab through a share exchange of newly issued shares of LGIQ for
This acquisition, valued at an estimated
Strategic Acquisition Highlights:
Valuation and Shareholder Interest: The preliminary target valuation of MedLab is set at
$100 million , with Logiq shareholders poised to retain15% post-transaction.Uplisting: post-transaction, the combined entity aims to meet listing qualifications for Nasdaq, CBOE, or NYSE and complete a substantial capital raise by the end of 2024.
Biotech Portfolio Expansion: This acquisition represents the first in a series of acquisitions targeting a cumulative value exceeding
$750 million , focusing on biotech and cell and gene therapy (CGT) assets.
About the Transaction: Logiq will acquire MedLab through a share exchange, issuing new Logiq shares for
CEO Brent Suen on the Acquisition: "The successful acquisition of MedLab marks a transformative milestone for Logiq, propelling us into the lucrative biotech domain. This strategic move enables us to develop groundbreaking treatments for serious illnesses. With access to proprietary laboratory technology, generating new ways to treat patients, and enabling the customization of cell and gene therapy for longevity, anti-aging, and life extension,"
MedLab Manager Daniel Vinokur on the Merger: "This merger marks a pivotal new chapter for MedLab. Aligning with Logiq not only grants us access to capital markets essential for delivering cell and gene therapies for longevity and life extension on a global scale but also sets the stage for significant new developments and growth. Our integrated approach from R&D to commercialization ensures we address the intricate demands of this complex field. With this merger, we are poised to embark on a new journey of innovation and expansion, with more acquisitions and strategic growth initiatives on the horizon,"
Anticipated Outcomes:
Capital Raise: The combined entity plans to secure a significant capital infusion in line with the transaction.
Uplisting Goals: As part of the anticipated financing, Logiq plans to transition from OTC Markets to a Nasdaq or NYSE listing by Q1 2025, making this a logical and imminent step to enhance its market presence and investor appeal.
Additional accretive acquisitions - Targeting six additional strategic acquistions that are in process now will provide a path to significant revenues by mid-2025.
MedLab's Unique Positioning:
Valuation: MedLab has secured a preliminary gross valuation of
$100 million for this transaction, reflecting its robust market potential.Innovation in Cell-Based Therapy: MedLab is at the forefront of developing cell-based therapy products for a range of medical conditions, including challenging cancers and age-related diseases.
Advanced Treatment Platform: Utilizing autologous adipose-derived mesenchymal stem cells, MedLab's platform integrates oncolytic viruses and therapeutic components, offering a novel and effective approach to treatment.
New Direction for Logiq: Logiq, founded in November 2004, is a technology company that was previously engaged in e-commerce solutions and services. Logiq recently sold part of its technology business and decided to change its direction by targeting the medical field, specifically engaging in the business of cell and gene therapy, longevity, anti-aging, and rejuvenation. Post acquisitions, Logiq will be managed by executives and R&D scientific staff with decades of experience.
At the forefront of innovation, Logiq is dedicated to transforming the landscape of health. The company specializes in pioneering medical solutions within the realms of drug development, medical devices, and rare disease modalities. Logiq's mission is to discover, manage, and support companies that share its vision of advancing health through cutting-edge technology and research.
Business Model:
Drug Development: Focusing on innovative therapies to address unmet medical needs.
Medical Devices/Remote Monitoring: Harnessing technology to enhance patient outcomes.
Rare Diseases: Exploring new frontiers in treatment for the most challenging conditions.
Strategic Partnerships: Collaborating with industry leaders to accelerate progress.
Sales & Marketing Support: Providing comprehensive backing to ensure success in competitive markets.
Human Resources Development: Cultivating a workforce that is as dynamic as the solutions provided.
Longevity Treatments: Logiq embraces longevity medicine, a proactive approach to extend healthy lifespan through personalized health plans. This emerging field utilizes advanced AI to decode the science of aging, offering treatments that not only add years to life but life to years.
Cell and Gene Therapy: Logiq's commitment extends to cell and gene therapy, revolutionary approaches that modify or replace genetic material to combat diseases at their root. These therapies hold the promise of lasting cures, marking a new era in medical treatment.
Strategic Partnerships and Equity Stakes: Logiq's strategic partnerships are designed to foster mutual growth and innovation. The company engages with clients and organizations to:
Collaborate on Research: Join forces with entities that complement Logiq's expertise in drug development and medical devices, enhancing collective R&D capabilities.
Share Technological Resources: Utilize AI tools and other advanced technologies to improve efficiency and outcomes in medical research and patient care.
Acquire Stakes: As part of its expansion strategy, Logiq considers acquiring minority stakes in partners' infrastructure, providing them with access to Logiq's resources and expertise.
Offer Equity Stakes: In return, Logiq offers equity stakes in its holding company, creating a symbiotic relationship that drives forward the shared vision for health innovation.
This approach not only strengthens Logiq's position in the market but also creates a network of interconnected entities, all working towards revolutionizing health through advancements in longevity treatments, cell, and gene therapy.
About MedLab Essentials: MedLab Essentials harnesses the power of cell and gene therapy to treat human disease. MedLab Bio is an advanced biotechnology company with a unique approach to the development of cell-based therapy products for various human indications. The company's expertise aligns with the industry's shift towards more accessible "off-the-shelf" therapies and expansion into life extensions.
The transaction is slated for completion by August 15, 2024, subject to standard closing conditions. This acquisition is the first of six biotech-focused companies, with subsequent acquisitions already in the LOI stage.
About Logiq: Logiq Inc., headquartered in the United States, revolutionizes e-commerce and digital customer acquisition by streamlining digital advertising. The company offers comprehensive, data-driven marketing solutions and software to engage customers across various channels.
Important Cautions Regarding Forward-Looking Statements: This press release contains certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the Safe Harbor created by those sections. This press release also contains forward-looking statements and forward-looking information that relates to Logiq's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result", "are expected to", "expects", "will continue", "is anticipated", "anticipates", "believes", "estimated", "intends", "plans", "forecast", "projection", "strategy", "objective" and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions, and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon.
Media & Investor Contact ir@logiq.com
SOURCE: Logiq, Inc.
View the original press release on accesswire.com
FAQ
What is the value of Logiq's acquisition of MedLab Essentials?
How will Logiq (LGIQ) acquire MedLab Essentials?
What percentage will Logiq (LGIQ) shareholders retain after the MedLab acquisition?
What are Logiq's (LGIQ) plans for uplisting after acquiring MedLab?
What is Logiq's (LGIQ) target for future acquisitions in the biotech sector?
